




RealRate

PHARMACEUTICAL 2021

BELLICUM PHARMACEUTICALS INC
Rank 140 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of BELLICUM PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BELLICUM PHARMACEUTICALS INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 559% points. The greatest weakness of BELLICUM PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 155% points.

The company's Economic Capital Ratio, given in the ranking table, is -44%, being 311% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	39,443
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,701
Liabilities, Non-Current	0
Other Assets	952
Other Compr. Net Income	-12
Other Expenses	0
Other Liabilities	344
Other Net Income	43,970
Property and Equipment	189
Research and Development	39,052
Revenues	2,891
Selling, General and Administrative Expense	15,531

Output Variable	Value in 1000 USD
Assets	40,584
Liabilities	25,045
Expenses	54,583
Stockholders Equity	15,539
Net Income	-7,722
Comprehensive Net Income	-7,728
Economic Capital Ratio	-44%